Trump Signs Order Easing Restrictions on Psychedelic Drugs and Treatments

President Donald Trump issued an executive order on April 18, 2026, to expedite access to research and treatments based on psychedelic drugs . The goal is to ease patient access to substances like psilocybin, ibogaine, LSD, and MDMA . This announcement has significant implications for the treatment of PTSD, depression, and other mental health problems .

Details on the executive order are still limited, but it is expected to accelerate research into the compounds' efficacy in treating a range of conditions . By signing the order, Trump's administration is taking steps to loosen restrictions on psychedelic drugs, potentially paving the way for broader use in medical research and treatment .

The executive order is a step in the direction of re-evaluating the potential therapeutic benefits of psychedelic substances, which have been gaining interest in mainstream medical research and therapy .